Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

TreeHouse Foods Faces Slowdown as Shoppers Cut Back on Even Cheaper Groceries

by Team Lumida
March 5, 2025
in Health and Longevity
Reading Time: 4 mins read
A A
0
high-angle photography of grocery display gondola

Photo by Peter Bond on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • TreeHouse Foods, a major supplier of private-label goods for retailers like Walmart and Target, is experiencing slower sales growth as inflation-weary consumers reduce spending on lower-cost groceries.
  • The company is focusing on cost-cutting measures, including supply-chain efficiencies and product adjustments, to protect margins in a challenging demand environment.
  • TreeHouse is expanding selectively through acquisitions while exiting less profitable product lines to streamline operations.
  • Analysts emphasize the need for operational improvements after recent production issues and recalls.

What Happened?

TreeHouse Foods, a leading manufacturer of private-label products for major retailers, is seeing a slowdown in sales growth as inflation-strained consumers cut back on even lower-cost grocery items. While private-label goods gained popularity during the pandemic and inflationary periods, demand has softened recently, with unit sales in key categories growing just 0.6% in late 2024 compared to 4.5% growth earlier in the year. In response, TreeHouse is implementing cost-saving measures, such as automating production processes and renegotiating supplier contracts, to reduce supply-chain costs by $250 million by 2027. The company is also refining its product portfolio, exiting less profitable areas like ready-to-drink beverages while expanding in others, including coffee and tea, through strategic acquisitions.


Why It Matters?

The slowdown in private-label sales reflects broader consumer behavior shifts as inflation continues to pressure household budgets. For investors, this signals potential headwinds for companies reliant on discretionary spending, even in traditionally resilient sectors like groceries. TreeHouse’s focus on cost control and profitability over aggressive sales growth highlights the challenges of navigating a softer demand environment. Additionally, operational missteps, such as production delays and product recalls, have weighed on the company’s performance, underscoring the importance of execution in maintaining investor confidence.


What’s Next?

TreeHouse plans to continue its cost-cutting initiatives while selectively expanding into high-growth areas like coffee and tea. The company’s ability to streamline operations and avoid further production issues will be critical to stabilizing its performance. Analysts expect slower growth in the near term, with TreeHouse forecasting a 3.5% decline in adjusted net sales for the first quarter of 2025. Investors should monitor the company’s progress in improving operational efficiency, managing its product portfolio, and adapting to evolving consumer spending patterns.

Source
Previous Post

China Strikes Back: Tariffs and Export Controls Escalate U.S.-China Trade War

Next Post

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

Recommended For You

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
5 days ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
7 days ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
2 weeks ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
2 weeks ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
3 weeks ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
3 weeks ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
1 month ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
1 month ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
1 month ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
1 month ago
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

The U.S. general fertility rate fell to 53.1 births per 1,000 women in 2025 — a record low — while the total fertility rate dropped to 1.57, well...

Read more
Next Post
blue UTP cord

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

gold and black metal tool

Gold Surges as Trade War Escalation Drives Demand for Safe-Haven Assets

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

woman in gray hoodie sweater jogging

This 55-Year-Old’s Simple Routine Beats Millionaires at Anti-Aging

May 17, 2024

SEC Transparency Rule Overturned: Impact on Private Equity and Hedge Funds

June 6, 2024
Capgemini to Acquire WNS for $3.3 Billion, Expanding AI-Powered Business Process Capabilities

Capgemini to Acquire WNS for $3.3 Billion, Expanding AI-Powered Business Process Capabilities

July 7, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018